ArticleClinical chemistry and laboratory medicine2026
Serial measurements of neuron specific enolase, glial fibrillary acidic protein and neurofilament light for mortality prediction in patients with severe acute brain injury in the ICU.
Article in Clinical chemistry and laboratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPrognostication in patients with severe acute brain injury (SABI) in the Intensive Care Unit (ICU) is complex, often requiring early decisions on life-sustaining therapy. Serum biomarkers such as neurofilament light (NFL), glial fibrillary acidic protein (GFAP) and neuron specific enolase (NSE) may aid in predicting outcomes. This study investigated the association between biomarker concentrations and hospital mortality in ICU patients with SABI.
methodsIn this prospective multi-center study, 103 adult ICU patients with SABI were enrolled within 24 h of injury. Serum concentrations (NFL, GFAP, NSE) were measured at 24 h, 72 h, 7 days, and 14 days post-injury. Biomarker concentrations between hospital survivors and non-survivors were compared using a linear mixed-effects model and ROC curves.
resultsGFAP concentrations peaked on day 1, while NSE and NFL concentrations peaked on day 14. Higher concentrations were observed in non-survivors for all biomarkers on day 3, a 1,4 fold increase for NSE (p=0.034) and approximately 2-fold increase for GFAP (p=0.041) and NFL (p=0.018). Distinct temporal patterns were observed for all biomarkers, although biomarker trajectories did not significantly differ between survivors and non-survivors. Prognostic accuracy was moderate when biomarkers were combined with established mortality predictors (AUC 0.749) on day 3.
conclusionsNSE, GFAP and NFL show distinct temporal trajectories in SABI patients. Concentrations were higher in non-survivors during the early phase of admission. While individual biomarkers showed limited prognostic accuracy, in combination with other predictors mortality prediction improved. Serum biomarkers may still be valuable in a multimodal prognostication framework for SABI patients.
Indexed as
Identifiers
41400634What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.